Idenix Pharmaceuticals Inc (IDIX)

24.50
0.05 0.20
Prev Close 24.45
Open 24.49
Day Low/High 24.46 / 24.50
52 Wk Low/High 2.93 / 24.50
Volume 5.09M
Avg Volume 2.96M
Exchange
Shares Outstanding 151.50M
Market Cap 3.71B
EPS -0.91
Div & Yield N.A. (N.A)
Idenix CEO Sees Hep C Treatment Boom

Idenix CEO Sees Hep C Treatment Boom

Once treatments for hepatitis C have a better cure rate, Ronald Renaud expects more people with the disease to seek treatment.

Gilead Suffers First Hep C Drug Setback

Gilead Suffers First Hep C Drug Setback

Gilead's GS-7977 fails to cure hard-to-treat hepatitis C patients, showing the wonder drug has flaws.

Hedge Funds Catch Hep C Fever

Hedge Funds Catch Hep C Fever

Some of Wall Street's largest investors, including SAC Capital's Steven Cohen are making big plays for hepatitis C drug stocks

BIO CEO Confab Live Blog Replay: Day 2

BIO CEO Confab Live Blog Replay: Day 2

Follow all the news and social media commentary from the BIO CEO & Investor Conference

BIO CEO Conference Live Blog

BIO CEO Conference Live Blog

Follow all the biotech news and social media conversation from the 2012 BIO CEO & Investor Conference.

Gilead, Vertex and the Mystery of Missing Hep C Patients

Gilead, Vertex and the Mystery of Missing Hep C Patients

Finding treatable Hep C patients will be harder than expected, so buying into Gilead's current valuation may not be wise.

3 Industries and 3 Stocks Riding a 2012 M&A Boom

3 Industries and 3 Stocks Riding a 2012 M&A Boom

Three industries that are off to a hot M&A start and some takeover candidates.

Idenix Stock Falls On Unusually High Volume (IDIX)

Idenix Stock Falls On Unusually High Volume (IDIX)

Idenix Pharmaceuticals (Nasdaq:IDIX) is trading at unusually high volume Friday with 7.2 million shares changing hands. It is currently at 4.1 times its average daily volume and trading down $1.67 (-12.7%).

Idenix Falls Casualty to Gilead Hep C Hoopla

Idenix Falls Casualty to Gilead Hep C Hoopla

Idenix shares falls on worries that its Hep C drug may not be competitive against a more potent rival from Gilead Sciences.

Idenix Stock Gaps Down On Today's Open (IDIX)

Idenix Stock Gaps Down On Today's Open (IDIX)

Shares of Idenix Pharmaceuticals (Nasdaq:IDIX) were gapping down Friday morning with an open price 11.7% lower than Thursday's closing price. The stock closed at $14.33 yesterday and opened today's trading at $12.65.

Biotech Stock Mailbag: Vical, Hep C Drugs

Biotech Stock Mailbag: Vical, Hep C Drugs

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Off the Charts

Off the Charts

After today's action, be prudent, clean up some excess longs and reduce risk.

BioLineRx: Tuesday's Hot Hep C Drug Stock

BioLineRx: Tuesday's Hot Hep C Drug Stock

The market's insatiable demand for Hep C speculative trades was met Tuesday by a little-known Israeli drug maker.

Idenix Pharma Buyout Likely: Survey

Idenix Pharma Buyout Likely: Survey

A group of Wall Street investors are bullish on Hep C drug stocks, including the belief that Idenix Pharma is the next takeover target.

Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger

Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Biotech Lessons Learned From JPM 2012

Biotech Lessons Learned From JPM 2012

Biotech stocks got off to a ripping start at the most closely watched healthcare conference of the year.

J.P. Morgan Biotech Confab Live Chat

J.P. Morgan Biotech Confab Live Chat

TheStreet's Adam Feuerstein will give his impressions of the J.P. Morgan Healthcare Conference and answer readers' biotech investing questions.

J.P. Morgan Biotech Confab Live Chat

J.P. Morgan Biotech Confab Live Chat

TheStreet's Adam Feuerstein will give his impressions of the J.P. Morgan Healthcare Conference and answer readers' biotech investing questions.

Idenix Pharma's Hep C Drug Safe But Slow (And Ready For Sale)

Idenix Pharma's Hep C Drug Safe But Slow (And Ready For Sale)

Idenix shares surge as the concerns about the safety of its hepatitis C drug appear to be lifted.

Stocks Drift Lower On First Day Of Earnings Season

Stocks Drift Lower On First Day Of Earnings Season

Stocks float higher in another quiet session on Wall St.; traders await corporate earnings

Hep C Takeover Speculation Rains Down on Idenix and Achillion

Hep C Takeover Speculation Rains Down on Idenix and Achillion

Bristol's $2.5 billion takeover of Inhibitex ignites speculation that Idenix and Achillion could be the next M&A targets.

Hep C Deal-A-Palooza: Bristol-Myers Buys Inhibitex for $2.5 Billion

Hep C Deal-A-Palooza: Bristol-Myers Buys Inhibitex for $2.5 Billion

The arms race to develop the next generation of hepatitis C therapies is escalating.

Biotech 2012 Kickoff Party: Investor Preview

Biotech 2012 Kickoff Party: Investor Preview

What every biotech investor needs to know before next week's J.P. Morgan Healthcare Conference.

Hep C Drug Panic! Pharmasset Stumble Ripples Through Sector

Hep C Drug Panic! Pharmasset Stumble Ripples Through Sector

Inhibitex, Idenix Pharma shares suffer as Pharmasset discloses liver problems with one of its hepatitis C drugs.

A Play Off Biotech Volatility

A Play Off Biotech Volatility

These Hep C drugmakers have taken a pummeling, so I'm entering a couple of aggressive trades here.

Idenix Stock Gaps Down On Today's Open (IDIX)

Idenix Stock Gaps Down On Today's Open (IDIX)

Shares of Idenix Pharmaceuticals (Nasdaq:IDIX) were gapping down Friday morning with an open price 14% lower than Thursday's closing price. The stock closed at $7.76 yesterday and opened today's trading at $6.67.

What's Next for Hep C Drug Stocks Following Gilead's $11B Pharmasset Buy?

What's Next for Hep C Drug Stocks Following Gilead's $11B Pharmasset Buy?

Gilead is criticized for overpaying for Pharmasset but more Hep C stock deals could be coming soon.

5 Stocks Under $10 With Big Upside Potential

5 Stocks Under $10 With Big Upside Potential

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Idenix Stock Falls On Unusually High Volume (IDIX)

Idenix Stock Falls On Unusually High Volume (IDIX)

Idenix Pharmaceuticals (Nasdaq:IDIX) is trading at unusually high volume Wednesday with 2.5 million shares changing hands. It is currently at 4.1 times its average daily volume and trading down 16 cents (-2.2%).

The Biotech Stock 13F Review: What Hedge Funds Were Buying and Selling

The Biotech Stock 13F Review: What Hedge Funds Were Buying and Selling

BioSante, Inhibitex and Idenix were among the drug stocks garnering attention from hedge funds in the third quarter.